MedTrace Logo

The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device

NCT03006055 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2017-01-02

No results posted yet for this study

Summary

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved. Application data of CellCollector in China is not available now. The purpose of this clinical trial is to confirm the validation and safety of CellCollector in Chinese patients.

Conditions

  • Circulating Tumor Cells.Breast

Interventions

DEVICE

Circulating tumor cells

Sponsors & Collaborators

  • Beijing Viroad Biotechnology Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006055 on ClinicalTrials.gov